ABOUT AJPP

The African Journal of Pharmacy and Pharmacology (AJPP) is published weekly (one volume per year) by Academic Journals.

African Journal of Pharmacy and Pharmacology (AJPP) is an open access journal that provides rapid publication (weekly) of articles in all areas of Pharmaceutical Science such as Pharmaceutical Microbiology, Pharmaceutical Raw Material Science, Formulations, Molecular modeling, Health sector Reforms, Drug Delivery, Pharmacokinetics and Pharmacodynamics, Pharmacognosy, Social and Administrative Pharmacy, Pharmaceutics and Pharmaceutical Microbiology, Herbal Medicines research, Pharmaceutical Raw Materials development/utilization, Novel drug delivery systems, Polymer/Cosmetic Science, Food/Drug Interaction, Herbal drugs evaluation, Physical Pharmaceutics, Medication management, Cosmetic Science, pharmaceuticals, pharmacology, pharmaceutical research etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in AJPP are peer-reviewed.

Contact Us

Editorial Office: ajpp@academicjournals.org
Help Desk: helpdesk@academicjournals.org
Website: http://www.academicjournals.org/journal/AJPP
Submit manuscript online http://ms.academicjournals.me/
Editors

Sharmilah Pamela Seetulsingh-Goorah
Associate Professor,
Department of Health Sciences
Faculty of Science,
University of Mauritius,
Reduit,
Mauritius

Himanshu Gupta
University of Colorado- Anschutz Medical Campus,
Department of Pharmaceutical Sciences, School of Pharmacy
Aurora, CO 80045,
USA

Dr. Shreesh Kumar Ojha
Molecular Cardiovascular Research Program
College of Medicine
Arizona Health Sciences Center
University of Arizona
Tucson 85719, Arizona,
USA

Dr. Victor Valenti Engracia
Department of Speech-Language and Hearing Therapy
Faculty of Philosophy and Sciences, UNESP
Marilia-SP, Brazil

Prof. Mahmoud Mohamed El-Mas
Department of Pharmacology,

Dr. B. Ravishankar
Director and Professor of Experimental Medicine
SDM Centre for Ayurveda and Allied Sciences,
SDM College of Ayurveda Campus,
Kuthpady, Udupi-574118
Karnataka (INDIA)

Dr. Manal Moustafa Zaki
Department of Veterinary Hygiene and Management
Faculty of Veterinary Medicine, Cairo University
Giza, 11221 Egypt

Prof. George G. Nomikos
Scientific Medical Director
Clinical Science
Neuroscience
TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC. 675 North Field Drive Lake Forest, IL 60045
USA

Prof. Sutiak Vaclav
Rovnikova 7, 040 20 Košice,
The Slovak Republic,
The Central Europe,
European Union
Slovak Republic
Slovakia

Dr. Caroline Wagner
Universidade Federal do Pampa
Avenida Pedro Anunciação, s/n
Vila Batista, Caçapava do Sul, RS - Brazil
Editorial Board

Prof. Fen Jicai
School of Life Science, Xinjiang University, China.

Dr. Ana Laura Nicoletti Carvalho
Av. Dr. Arnaldo, 455, Sao Paulo, SP, Brazil.

Dr. Ming-hui Zhao
Professor of Medicine
Director of Renal Division, Department of Medicine
Peking University First Hospital
Beijing 100034
PR. China.

Prof. Ji Junjun
Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China.

Prof. Yan Zhang
Faculty of Engineering and Applied Science, Memorial University of Newfoundland, Canada.

Dr. Naoufel Madani
Medical Intensive Care Unit
University hospital Ibn Sina, University Mohamed V Souissi, Rabat, Morocco.

Dr. Dong Hui
Department of Gynaecology and Obstetrics, the 1st hospital, NanFang University, China.

Prof. Ma Hui
School of Medicine, Lanzhou University, China.

Prof. Gu Huijun
School of Medicine, Taizhou University, China.

Dr. Chan Kim Wei
Research Officer
Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra, Malaysia.

Dr. Fen Cun
Professor, Department of Pharmacology, Xinjiang University, China.

Dr. Sirajunnisa Razack
Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.

Prof. Ehab S. EL Desoky
Professor of Pharmacology, Faculty of Medicine
Assiut University, Assiut, Egypt.

Dr. Yakisich, J. Sebastian
Assistant Professor, Department of Clinical Neuroscience
Karolinska University Hospital, Huddinge 141 86 Stockholm, Sweden.

Prof. Dr. Andrei N. Tchernitchin
Head, Laboratory of Experimental Endocrinology and Environmental Pathology LEEPA
University of Chile Medical School, Chile.

Dr. Sirajunnisa Razack
Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.

Dr. Yasar Tatar
Marmara University, Turkey.

Dr. Nafisa Hassan Ali
Assistant Professor, Dow Institute of Medical Technology
Dow University of Health Sciences, Chand bbi Road, Karachi, Pakistan.

Dr. Krishnan Namboori P. K.
Computational Chemistry Group, Computational Engineering and Networking,
Amrita Vishwa Vidyapeetham, Amritanagar, Coimbatore-641 112 India.

Prof. Osman Ghani
University of Sargodha, Pakistan.

Dr. Liu Xiaoji
School of Medicine, Shihzei University, China.
# ARTICLES

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy of Tribulus terrestris extract and metformin on fertility indices and oxidative stress of testicular tissue in streptozotocin-induced diabetic male rats</td>
<td>1088</td>
</tr>
<tr>
<td>Hend M. Tag, Heba M. A. Abdelazek, Yasmen S. Mahoud and Nahla S. EL-Shenawy</td>
<td></td>
</tr>
<tr>
<td>Investigating extemporaneous compounding practices in the Polokwane tertiary hospital pharmacies in South Africa - a pilot study</td>
<td>1099</td>
</tr>
<tr>
<td>Euphenia Mathebule Masupye, Fatima Suleman and Thirumala Govender</td>
<td></td>
</tr>
</tbody>
</table>
Efficacy of *Tribulus terrestris* extract and metformin on fertility indices and oxidative stress of testicular tissue in streptozotocin-induced diabetic male rats

Hend M. Tag¹, Heba M. A. Abdelazek², Yasmn S. Mahoud¹ and Nahla S. EL-Shenawy¹*

¹Zoology Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt.
²Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt.

Received 21 September, 2015; Accepted 27 November, 2015

The present study aimed at evaluating the effect of *Tribulus terrestris* on different parameters of oxidative stress and enzymatic/non-enzymatic antioxidant as well as the number, viability and abnormalities of sperm in testis tissues of male rats after induction of diabetes. The animals were divided into six groups; group I (control) was administered vehicle only, group II was treated with metformin (MET) and those in group III were given *T. terrestris* plant extract (TT extract). Group IV acted as positive diabetic control, group V and VI were diabetic animals treated with MET and TT-extract, respectively. The treatments were continued for 5 days/week for 60 days. Various oxidative stress parameters such as lipid peroxidation and activity of antioxidant enzymes were used to confirm the peroxidant state of animals as an effect of different treatments. *T. terrestris* was noticed to reduce the oxidative stress levels, and restore antioxidant enzyme activity in testis tissues as well as to improve the lipid profile content in serum. Histological analysis showed that *T. terrestris* treatment decreased testis tubular damage, and restored it to normal morphology. It can be concluded that TT extract as compared to metformin has potential effect against spermatotoxic and testicular toxicity and it can improve redox state in diabetic male rats.

**Key words:** *Tribulus terrestris*, oxidative/antioxidant, fertility indices, diabetes.

**INTRODUCTION**

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both (Thévenod, 2008; Bai et al., 2011; Wankeu-Nya et al., 2014). Sustained higher levels of blood glucose cause damage to nerves and blood vessels, leading to complications such as erectile dysfunction (ED) (Thorve, 2011; Cao et al., 2012). DM is one of the predominant risk factors of ED and also one of the most difficult to treat (Chitaley et al., 2009). DM may cause ED through a number of pathophysiologic changes, including neuropathy, endothelial dysfunction and hormonal changes (Konstantinos and Dimitrios, 2008).
Although pathophysiologic changes may be more pronounced in type 1 diabetes than in type 2, they are mainly due to oxidative stress, through the formation of oxygen free radicals and advanced glycation end-products (AGEs) (Giacco and Brownlee, 2010; Ramesh et al., 2012). Streptozotocin (STZ) induces diabetes mellitus by destroying pancreatic β-cells, possibly through generating excess reactive oxygen species (ROS) (Yamagishi et al., 2001). STZ generated lipid peroxidation (LPO) and DNA breaks in pancreatic islets cells have been demonstrated (Lenzen, 2008). Exaggerated production of these reactive species in diabetes can lead to very serious problems including cardiovascular disease, liver and kidneys failure, blindness, and nerve injury (Neyenwe et al., 2011; El-Shenawy et al., 2013). Due to multiple action of streptozotocin intoxication, understanding how uncontrolled hyperglycemia impacts the sexual function and seeking for efficient drugs able to alleviate diabetes-induced complications are yet important areas of inquiry. However, despite the increasing availability of effective conventional medical treatments for erectile dysfunction induced complications are yet important areas of inquiry. However, despite the increasing availability of effective conventional medical treatments for erectile dysfunction in diabetic patients, plant-derived and herbal remedies continue to provide a popular alternative for diabetic men seeking to improve their sexual life (Watcho et al., 2007; Yakubu and Afolayan, 2009).

Thus, antioxidant therapy is one of the strategies for diabetes treatment. Many herbal extracts or derivatives with high antioxidant activity are useful for treatment of diabetes and other metabolic syndrome (Samad et al., 2009). Several plant extracts are known to have antidiabetic properties and a large number of compounds from plant extracts have been reported to have beneficial effects for the treatment of DM (Ramesh et al., 2010). Diabetes can be managed by diet, exercise and chemotherapy. However, the pharmacological drugs are either too expensive or have undesirable side effects or contraindications (Maiti et al., 2008). Throughout the world, many traditional plant treatments for diabetes exist, and therein lies a hidden wealth of potentially useful natural products for the control of diabetes. Natural plant drugs are frequently considered to be less toxic and free from side effects than synthetic ones (Ramesh et al., 2012; Sunil et al., 2009).

*Tribulus terrestris* (TT) is a member of the Zygophyllaceae family and a natural herb. It is widely distributed in Africa, Mediterranean region western Asia, China, Japan, Korea and Europe (Mohammed et al., 2013). TT is used in the folk medicine against sexual impotence, edema, abdominal distention and cardiovascular diseases (Chhatre et al., 2014). It has been shown to increase the free serum testosterone (Brown et al., 2001) and it possesses aphrodisiac activity probably due to androgen increasing property of TT (Mohammed et al., 2013). Tribulus has no significant side effects if used at the safe range of 250 to 750 mg/day (Heidari et al., 2007). TT extract contains many compounds such as alkaloids, flavonoids oil, saponins, resins and nitrates (Adaay and Mosa, 2012), possesses antihypertensive activity (Braca et al., 2001) and hypolipidemic effect (Chu et al., 2003). Amin et al. (2006) found that the ethanolic extract of TT exhibits a significant antioxidant activity against STZ-induced diabetes in liver tissues without explaining the mechanism of protection.

Moreover, Kamboj et al. (2011) reported that TT is an extraneous antioxidant, reduced oxidative stress, maintained proper renal functioning and reduced renal injury. Metformin, glucose-lowering agent, is commonly used for the treatment of type 2 diabetes. Decreasing hepatic glucose production through gluconeogenesis suppression and activating peripheral glucose utilization in muscle, intestine and liver have been reported to be contributors to the glucose-lowering effect of metformin (Yoshida et al., 2009), but the primary effect of metformin on glucose-lowering remains unknown. Therefore, the present study focused on a comparison between the chronic effect of metformin and aqueous extract of TT as a direct gluconeogenesis inhibitor and subsequently, its effects on lipid profile, serum testosterone and follicle stimulating hormones levels, semen quality and oxidative parameters of testicular tissues of streptozotocin-induced diabetic male rats. This could facilitate further understanding of the implications of the difference in mechanisms between metformin and TT extract in terms of clinical usage for the treatment of diabetes. Moreover, the histological examination of testis was evaluated.

**MATERIALS AND METHODS**

**Chemicals**

STZ was purchased from Sigma Co. (St. Louis, MO). Thiobarbituric acid aqueous solution (TBA), n-butanol, pyridine, 1,1,3,3-tetramethoxypropane standard, trichloroacetic acid (TCA), phosphate buffer, 5,5-dithiobis(2-nitrobenzoic acid) (DTNB) and reduced glutathione (GSH) standard were obtained from Fluka (Taufkirchen, Germany). All the chemicals used were analytical grade. The assay kits for cholesterol, triacylglycerol, low density lipoprotein cholesterol (LDL-C), and high density lipoprotein cholesterol (HDL-C) were obtained from BioDiagnostic Company, Giza, Egypt.

**Plant materials collection and preparation of extracts**

*T. terrestris* fruits were obtained from the local market of herbs, Ismailia, Egypt. The plant was identified and authenticated by Botany Department, Faculty of Science, Suez Canal University, Ismailia Egypt. Fruits were ground into a fine powder. For the aqueous extraction, hundred grams (100 g) of the powdered fruit were extracted using 200 mL of distilled water in Soxhlet extraction system for 12 h. The extract was evaporated using rotary evaporator at 40°C under reduced pressure close to dryness (gummy residue). The yield was found to be 12%. The gummy residue was dissolved in appropriate volume of distilled water and stored at -20°C until use (Eagappan et al., 2015).

**Phytochemical screening**

The phytochemical profile was performed as described by Costa...
Preparation of standard drug (MET)

Metformin hydrochloride (500 mg/tablet) was purchased from a local pharmacy. Three tablets of drug were ground to fine powder and dissolved in 100 mL distilled water. Rat dose of metformin was calculated from the standard clinical human dose on the basis of surface area [rat dose = \((\text{human dose/average body weight of rats}) \times 7\)] (Freireich et al., 1966).

Animals

Healthy adult male albino rats of the Wistar strain, 4–5 months of age and weighing 170–190 g, were supplied from the Animal Breeding House in Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt. They were maintained at room temperature with a natural light : dark cycle (12:12 h) and provided with standard diet and water ad libitum. The experiments were performed in accordance with the internationally accepted standard ethical guidelines for laboratory animal use and care as described in the European Community guidelines: EEC Directive 86/609/EEC, of the 24th November 1986 (European Communities, EC, 1986). Rats were acclimatized to the laboratory environment for a week prior to the start of experiments.

Induction of diabetes

Diabetes was induced in 16 h fasted male rats by a single intraperitoneal injection of a buffered solution (0.1 M citrate, pH 4.5) of streptozotocin at the dose 55 mg/kg. To prevent hypoglycemia, animals were given a 10% glucose solution for the next 48 h. Blood glucose level was measured 3 days after diabetes induction using reagent strips (Accu-Chek®, Roche). Blood was collected from tail vein and rats with blood glucose values more than 200 mg/dL were considered diabetics.

Experimental design

A total of 36 rats (18 diabetic rats; 18 normal rats) were randomly divided into six groups of 6 animals each and treated as follows: Group 1, normal rats were received the vehicle (10 mL/kg of distilled water), group 2, normal rats were treated with MET (350 mg/kg/day) (Owolabi and Omogbai, 2012), group 3, normal animals treated with TT aqueous extracts (10 mg/kg) (Gauthaman et al., 2003). Groups 4, 5 and 6, diabetic rats treated with vehicle, MET and TT aqueous extract, respectively. All the animals were treated orally by gastric tube daily for eight weeks.

Sperm quantity and quality

Determination of sperm characteristics and morphology

Left caudal epididymis was weighed, diluted in 1:20 with physiological saline (0.9% NaCl) solution in a Petri dish and minced with a scalpel blade in the mid-to-distal region. Suspension was kept at 37°C for 5 min for the dispersion of sperm into medium.

Sperm count

Sperm count was determined using Neubauer chamber (Deep 1/10 mm, LAMBART, Darmstadt, Germany) of hemocytometer following the method as described by Pant and Srivastava (2003) and total number of the sperm head counted at 40x magnification. Each sample was counted twice and means value was taken for calculation. Sperm count was expressed as number of sperm per ml of solution.

Sperm viability and abnormalities

Sperm suspension was pipetted very gently 20 times and placed in a hemocytometer. Sperm were stained with eosin-nigrosine staining method to evaluate the viability and abnormalities (NAFA, 2002). Sperm morphology was viewed under a light microscope (Nikon, H600L, Tokyo, Japan) under 400× magnifications. Percentages of sperm head and acrosome abnormalities were evaluated on air-dried eosin-nigrosine stained slide and were expressed as a percentage for abnormalities (Evans and Maxwell, 1987). Data was expressed as percentage of morphologically abnormal sperm to total sperm count.

Body and genital organ weight

At the end of experiment, the testes and accessory sex organs (seminal vesicles, prostates and epididymis) were dissected out, trimmed off the attached tissues and weighed individually. Then, the organ/body weight ratio was calculated.

Biochemical assays

Blood samples were collected after 60 days of treatment from anaesthetized animals groups from retro-orbital venous plexus (Itziar et al., 2010) with a fine sterilized glass capillary tube into heparin-coated and dry tube. The gathered blood were left for 20 min at room temperature, then centrifuged at 3000 rpm (600 g) for 10 min for the separation of sera. The sera were kept in a deep freezer (at -20°C) until analyses of certain biochemical parameters. The biochemical measurements were performed according to the details given in the kit’s instructions.

Hormonal determination

Serum testosterone concentrations were determined using a solid phase enzyme-linked immunosorbsent assay (ALPCO Diagnostics, Cat No. 55-TESMS-E01, USA) based on the principle of competitive binding. An unknown amount of testosterone present in the sample and a defined amount of testosterone conjugated to horseradish peroxidase compete for the binding sites of testosterone antiserum coated to the wells of a microplate. After one-hour incubation on a shaker the microplate was washed four times. The concentration of testosterone is inversely proportional to the optical density measured (Darney et al., 1996). Follicle-stimulating hormone (FSH) was determined using a kit (ALPCO Diagnostics, Cat No. MBS810666, USA), that depend on double-antibody sandwich enzyme-linked immunosorbsent assay (Knobil, 1980).

Determination of serum lipid profile

The serum total cholesterol (TC) and triglycerides (TG) were determined according to the methods described by Richmond (1973) and Fossati and Prencipe (1982), respectively. High density lipoprotein–cholesterol (HDL–c) was determined according to the methods of Lopez et al. (1977). Serum LDL–cholesterol (LDL–c)
level was calculated according to Friedewald (1972) formula: LDL-c = total cholesterol - (HDL-c + triglycerides)/5. Very low density lipoprotein cholesterol (VLDL-c) levels were calculated by using the following formula of Prakash et al. (2003): VLDL-c = triglyceride/5.

Preparation of homogenate tissue

The excised testicular tissue was washed with deionized water for the removal of blood, and later the fatty parts were removed. Homogenization was performed in a phosphate buffer solution with a pH value adjusted to 7.4, and the supernatant was separated by means of centrifugation at 20,000 rpm for 1 h. The supernatant and hemolysate obtained were used for the analyses of all oxidative and antioxidant parameters.

Lipid peroxidation (LPO) level: Lipid peroxidation was determined in supernatant of homogenate testicular tissue by the thiobarbituric acid (TBA) method which estimates the malondialdehyde formation (MDA) according to Esterbauer and Cheeseman (1990). The concentration of MDA was calculated by the absorbance coefficient of MDA–TBA complex (1.56 X10^5 M^-1 cm^-1). LPO was expressed as nano moles MDA/g tissue.

Antioxidant enzymes: The specific activity of testicular superoxide dismutase (SOD, EC 1.15.1.1) was determined according to the method described by Misra and Fridovich (1972). Activity of SOD was expressed as units/mg protein. The testicular catalase (CAT) activity (CAT; EC 1.11.1.6) was measured spectrophotometrically at 240 nm by calculating the rate of degradation of H2O2, the substrate of the enzyme (Aebi, 1984). Activity of catalase (CAT) was expressed as units/mg protein. Glutathione peroxidase (GPx) activity was determined as described by Hafeman et al. (1974). The peroxide substrate (ROOH), glutathione reductase (GR) and NADPH are included in the reaction mixture. The formation of oxidized form of glutathione (GSSG) catalyzed by GPx is coupled to the recycling of GSSG back to reduced form of glutathione (GSH) using GRx. NADPH is oxidized to NADP+ The change in A 340 due to NADPH oxidation is monitored and is indicative of GPx activity. Glutathione-S-transferase (GST; EC 2.5.1.18) activity of testicular tissue was measured spectrophotometrically by the method of Alin (1985) using S-2,4-dinitrophenyl glutathione (CDNB) as a substrate. The activity of GST was expressed in terms of μmol/min/mg protein.

Reduced glutathione content: Reduced glutathione content (GSH) of supernatant was performed by the method of Beutler (1963) using commercial glutathione reduced kits (Bio diagnostic for diagnostic reagents: Dokki, Giza, Egypt). Determination of GSH is based on the reaction of DTNB (50,5- dithiobis-(2-nitrobenzoic acid)) with GSH and yield of a yellow colored chromophore; 5-thio-nitrobenzoic acid with a maximum absorbance at 412 nm. The amount of GSH present in the testicular tissue was calculated as nano moles GSH/g tissue.

Histopathological evaluation

Histological examination of the tissue was conducted after removal of testis from rats. The tissues were gently rinsed with a physiological saline solution (0.9% NaCl) to remove blood and adhering debris. Testes were taken and fixed in a 10% neutral-buffered formalin solution for 24 h. The fixed specimens were then trimmed, washed and dehydrated in ascending grades of alcohol. These specimens were cleared in xylene, embedded in paraffin, sectioned at 4–6 μm thickness and stained with Hematoxylin and Eosin (H&E) then examined microscopically according to Luna (1968).

Statistical analysis

Data are expressed as mean values ± SE (n = 6). Statistical analysis was performed using one-way analysis of variance (ANOVA) to assess significant differences among treatment groups. For each significant effect of treatment, the post hoc Tukey’s test was used for comparisons. The criterion for statistical significance was set at P < 0.05. All statistical analyses were performed using SPSS statistical version 20 software package (SPSS Inc., USA).

RESULTS

Phytochemical screening

Qualitative phytochemical screening of aqueous extracts of TT showed the presence of alkaloids, tannins, saponins and cardiac glycosides.

Sperm characteristics and relative organs weight

Figure 1 shows the effect of treatment of TT-extract on sperm characteristics in diabetic rats. Our findings indicate that in diabetic rats, sperm count was 77.66% lower than normal, non-diabetic rats. In diabetic rats, total sperm count was approximately 33.0 ± 15.21 million/mL which was lesser than the normal rats. 60-days treatment with the MET or TT-extract caused a significantly higher count (2.33- and 2.73-fold, respectively) as compared to non-treated diabetic rats. No significant difference in the count was noted between treatment with MET and TT-extract.

The sperm viability was 28.0% in diabetic rats than normal, non-diabetic rats, while the viability was 66.0% for control animals (Figure 1). 60-days treatment with MET resulted in a significant increase in the viability to 49%. Meanwhile, treatment with TT-extract caused increase in sperm viability of diabetic rats, significantly to normal value of control (60.0%).

Figure 1 shows percentages of abnormal sperm in control and treatment groups. Sperm morphology assessment showed that the sperm abnormalities (head and tail) were more frequent in diabetic male rats (60%) than those of the normal control (17%). On the other hand, the sperm abnormalities reduced (P < 0.05) in normal group treated with the TT-extracts for 60 days to 10%. When the diabetic groups received MET or TT-extract, the abnormality decreased by 33 and 29%, respectively as compared to those of the diabetic animals.

The tissue weights expressed as relative organ weights are shown in Table 1. Changes in the relative weights of the testes were recorded among all the treated-group. Significantly lower relative weights of the prostate glands vs. controls were found in the diabetic-group. In groups treated with MET and TT extract, a significant (P<0.01) decrease in the relative mass of the prostate was also found as compared to diabetic animals. No difference in
Figure 1. Sperm evaluation in control and diabetic male albino rats treated with MET and TT extract. Values as mean ± SEM. n=6, One Way ANOVA followed by Duncan multiple comparison tests. a p<0.05 when compared with normal control group, b p<0.05 when compared with diabetic group.

Table 1. Effect of MET and TT extract on relative organ weight in normal and streptozotocin-induced diabetic rats

<table>
<thead>
<tr>
<th>Groups and Treatment</th>
<th>Testes Mean ± SE (g)</th>
<th>Seminal vesicles Mean ± SE (g)</th>
<th>Prostate glands Mean ± SE (g)</th>
<th>Epididymis tail Mean ± SE (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.65±0.051</td>
<td>0.36±0.015</td>
<td>0.24±0.017</td>
<td>0.07±0.007</td>
</tr>
<tr>
<td>MET</td>
<td>0.77±0.085</td>
<td>0.36±0.011</td>
<td>0.29±0.008</td>
<td>0.13±0.016</td>
</tr>
<tr>
<td>TT extract</td>
<td>0.76±0.025</td>
<td>0.31±0.012</td>
<td>0.23±0.015</td>
<td>0.23±0.166</td>
</tr>
<tr>
<td>Diabetic</td>
<td>0.28±0.023&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.13±0.008&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.05±0.004&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.03±0.001</td>
</tr>
<tr>
<td>Diabetic and MET</td>
<td>0.51±0.024&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.29±0.017&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.19±0.008&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.06±0.000</td>
</tr>
<tr>
<td>Diabetic and TT extract</td>
<td>0.62±0.121&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.18±0.044&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.18±0.310&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.09±0.013</td>
</tr>
</tbody>
</table>

Values as mean ± SEM. n=6, One way ANOVA followed by Duncan multiple comparison tests. <sup>a</sup> p<0.05 when compared with normal control group, <sup>b</sup> p<0.05 when compared with diabetic group.

Table 1 shows that after eight weeks of treatment, apart from the treated control rats (MET and TT-extract groups) where the blood glucose continued to increase, those groups remained statistically unchanged as compared to their respective baseline values (initial blood glucose level) but remained high as compared to the normal control rats. Diabetic rats displayed characteristic high blood glucose and low plasma insulin levels. The glucose levels decreased significantly by 55.19 and 34.91% after treating the diabetic rat with MET and TT-extract, respectively. The levels of insulin were improved significantly in the groups treated with MET and TT-extract by 2.55- and 3.0-fold, respectively.

As shown in Figure 2, TT extract treatment increased significantly, the serum testosterone levels in diabetic animals as compared to the diabetic rats by 2.79-fold. The treatment of diabetic rat with MET increased the level of testosterone by 2.33-fold as compared to diabetic-group. FSH increased significantly in diabetic

**Biochemical parameters**

Table 2 shows that after eight weeks of treatment, apart from the treated control rats (MET and TT-extract groups) where the blood glucose continued to increase, those groups remained statistically unchanged as compared to their respective baseline values (initial blood glucose level) but remained high as compared to the normal control rats. Diabetic rats displayed characteristic high blood glucose and low plasma insulin levels. The glucose levels decreased significantly by 55.19 and 34.91% after treating the diabetic rat with MET and TT-extract, respectively. The levels of insulin were improved significantly in the groups treated with MET and TT-extract by 2.55- and 3.0-fold, respectively.
Table 2. Effect of MET and TT extract on blood glucose and insulin levels in normal and streptozotocin-induced diabetic rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Glucose (mg/dL)</th>
<th>Insulin (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>93.40 ± 2.04</td>
<td>1.20 ± 0.08</td>
</tr>
<tr>
<td>MET</td>
<td>104.20 ± 7.12</td>
<td>0.92 ± 0.03</td>
</tr>
<tr>
<td>TT extract</td>
<td>110.20 ± 2.69</td>
<td>0.82 ± 0.04</td>
</tr>
<tr>
<td>Diabetic</td>
<td>212.00 ± 11.58&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.20 ± 0.01&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic and MET</td>
<td>95.60 ± 3.64&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.71 ± 0.01&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic and TT extract</td>
<td>138.20 ± 15.84&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.80 ± 0.11&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Values as mean ± SEM, n=6, One way ANOVA followed by Duncan multiple comparison tests. <sup>a</sup> p<0.05 when compared with normal control group, <sup>b</sup> p<0.05 when compared with diabetic group.

Figure 2. Testosterone and FSH levels in control and diabetic male albino rats treated with MET and TT extract. Values as mean ± SE (n=6), One way ANOVA followed by Duncan multiple comparison tests. <sup>a</sup> p<0.05 when compared with normal control group, <sup>b</sup> p<0.05 when compared with diabetic group.

Rats by 3.94-fold as compared to the control animals (Figure 2). FSH was reduced by 49.27 and 46.83% in diabetic rats treated with MET and TT extract, respectively as compared to diabetic animals.

All the parameters of lipid profile (TC, TG, LDL-c and VLDL-c) were increased except the HDL-c which was decreased in diabetic rats (Table 3). The effect of TT extract on the lipid profile of the diabetic rats was significantly different from the MET-treated group. Treatment of the TT extract to diabetic group significantly decreased TC, TG, LDL-c and VLDL-c as compared to MET-group.

Our results revealed an increase of LPO in the testis of the diabetic-treated group as evidenced by the enhanced malondialdehyde levels in the testis homogenates as compared to negative the controls (Table 4). The administration of MET and TT extract alleviated LPO induced by STZ treatment and significantly modulated the malondialdehyde levels in the testis of rats by 62.19 and 65.74%, respectively.

The result clearly indicated that treatment with MET resulted in a significant increase in the activity of testes GST as compared to diabetic animals by 1.66-fold (Table 4). However, diabetic rats treated with TT-extract showed significant increase in GST by 1.33-fold as compared to diabetic rats.

The result of testicular reduced glutathione (GSH) level is presented in Table 4. These results indicated that
treating the rats with STZ resulted in a significant decrease in the level of testes GSH as compared to the control animals. When TT-extract was administrated to diabetic animals, it was capable of recovering the GSH level to approximately the normal values (Table 4). It has been noticed in the GSH levels that there is increase by healing effects against STZ induced diabetes testicular damage, showing sperm with normal morphology and concentration.

These changes were markedly reduced with oral administration MET or TT-extract, revealing a marked repairing of testicular abnormalities, as shown in Figure 3E and F, demonstrating maximum antioxidant and healing effects against STZ induced diabetes testicular damage, showing sperm with normal morphology and concentration close to the control group. Histopathological findings are in accordance with the results of the above studied parameters for testicular toxicity.

**DISCUSSION**

The aim of the present study was to evaluate the aphrodisiac effects of the aqueous extract of TT in streptozotocin-induced type 1 diabetic rats. Streptozotocin-induced type 1 diabetes in rats provides a relevant model to study the reproductive dysfunction under diabetic conditions, as they exhibit a number of reproductive deficits that resemble those seen in human diabetics (Soudamani et al., 2005). It is well known that diabetes is positively associated with lowered male fertility and sexual dysfunction (Shalaby and Mounier, 2010).

To the best of our knowledge, this study reported for

**Table 3. Effect of MET and TT extract on lipid profile levels in normal and streptozotocin-induced diabetic rats.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>TC (mg/dl)</th>
<th>TG (mg/dl)</th>
<th>HDL-c (mg/dl)</th>
<th>LDL-c (mg/dl)</th>
<th>VLDL-c (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>107.40±2.77</td>
<td>66.75±2.84</td>
<td>39.92±1.11</td>
<td>80.83±1.52</td>
<td>13.35±0.65</td>
</tr>
<tr>
<td>MET</td>
<td>92.10±1.72a</td>
<td>82.20±1.67a</td>
<td>32.70±0.83</td>
<td>75.82±1.19a</td>
<td>16.42±0.34a</td>
</tr>
<tr>
<td>TT extract</td>
<td>70.00±5.07a</td>
<td>86.00±2.63a</td>
<td>34.88±0.85a</td>
<td>44.28±5.335</td>
<td>9.16±0.43a</td>
</tr>
<tr>
<td>Diabetic</td>
<td>165.05±7.87a</td>
<td>102.80±4.92a</td>
<td>29.39±1.45a</td>
<td>156.22±7.50a</td>
<td>20.56±0.98a</td>
</tr>
<tr>
<td>Diabetic and MET</td>
<td>121.99±6.02b</td>
<td>75.63±2.90b</td>
<td>35.11±1.86b</td>
<td>102.00±5.12b</td>
<td>15.13±0.58b</td>
</tr>
<tr>
<td>Diabetic and TT extract</td>
<td>86.04±2.66b, c</td>
<td>51.65±4.97b, c</td>
<td>35.20±1.77b</td>
<td>61.46±4.40b, c</td>
<td>10.30±0.99b, c</td>
</tr>
</tbody>
</table>

TC, Total cholesterol; TG, triglycerides; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; VLDL, very low density lipoprotein cholesterol. Values as mean ± SEM. n=6, One Way ANOVA followed by Duncan multiple comparison tests. *p<0.05 when compared with normal control group, **p<0.05 when compared with diabetic group c when compared with diabetic animals treated with MET.

**Table 4. Effect of MET and TT extract on oxidative/antioxidant parameters of normal and streptozotocin-induced diabetic rats.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>MDA (µmol/mg tissue)</th>
<th>CAT activity (mmol/min/mg tissue)</th>
<th>GST (mmol / mg tissue)</th>
<th>GSH (mg/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>109.00±3.28</td>
<td>34.69±4.66</td>
<td>22.00±0.83</td>
<td>49.00±1.21</td>
</tr>
<tr>
<td>MET</td>
<td>173.20±9.41a</td>
<td>44.22±8.49</td>
<td>19.60±0.74</td>
<td>45.40±2.16</td>
</tr>
<tr>
<td>TT extract</td>
<td>148.00±10.75a</td>
<td>44.39±5.44</td>
<td>21.20±2.22</td>
<td>52.80±0.37</td>
</tr>
<tr>
<td>Diabetic</td>
<td>556.00±26.39a</td>
<td>13.30±0.73a</td>
<td>12.80±1.11a</td>
<td>8.40±0.40</td>
</tr>
<tr>
<td>Diabetic and MET</td>
<td>210.20±26.69b</td>
<td>26.19±2.35b</td>
<td>21.20±1.31b</td>
<td>32.00±2.03</td>
</tr>
<tr>
<td>Diabetic and TT extract</td>
<td>190.50±8.11b</td>
<td>38.11±2.12b</td>
<td>17.00±2.91b</td>
<td>37.40±1.69</td>
</tr>
</tbody>
</table>

Values as mean ± SEM. n=6, One way ANOVA followed by Duncan multiple comparison tests. *p<0.05 when compared with normal control group, **p<0.05 when compared with diabetic group.

**Histological study**

Figure 3 illustrates the histological examination of testicular tissues of different treatment groups. Testicular histology of control group revealed normal spermatogenesis, depicting all the germ cells types, viz. spermatogonic, primary spermatocytes (non-pachytene and pachytene) and spermatids (round and elongated), sperms with normal morphology and concentration in the seminiferous tubules. The Sertoli and interstitial Leydig cells are also showed normal morphology (Figure 3A). Moreover, all layers of germ cells had normal basement membrane and interstitial tissue. Figure 3B and C shows normal testis of control rats treated separately with MET and TT-extract, respectively. Figure 3D demonstrates that diabetes caused degenerative changes such as loss of germ cells, abnormality of germative epithelium, interruption in meiosis, sperm with abnormal shape and concentration.

The aim of the present study was to evaluate the aphrodisiac effects of the aqueous extract of TT in streptozotocin-induced type 1 diabetic rats. Streptozotocin-induced type 1 diabetes in rats provides a relevant model to study the reproductive dysfunction under diabetic conditions, as they exhibit a number of reproductive deficits that resemble those seen in human diabetics (Soudamani et al., 2005). It is well known that diabetes is positively associated with lowered male fertility and sexual dysfunction (Shalaby and Mounier, 2010).
the first time comparison of the effect of TT-extract and MET on sperm characteristics and oxidative stress in testis of diabetic rats. Higher sperm count, percentages of sperm forward motility, viability and lower percentage of abnormal sperm were observed following TT-extract treatment to STZ-induced diabetic rats. Moreover, it increased the weight of testes and seminal vesicles and decreased blood glucose level, but increased serum insulin and testosterone as well as FSH levels and ameliorated the degenerative lesions seen in the testes of diabetic rats. Our findings have further shown that TT extract was able to lower the level of testis oxidative stress as evident from lower amount of LPO and the higher activities of endogenous antioxidant enzymes (SOD and CAT) as well as the non-enzymatic antioxidant (GSH) in testis of diabetic rats.

An evaluation of sperm characteristics is useful when investigating the underlying cause of male infertility (WHO, 2010). In the present study, TT extract administration to diabetic rats prevented or reduced impairment in sperm characteristics, abnormal sperm percentages and abnormal appearances of sperm. The effect of diabetes on these sperm end point parameters was consistent with other reports in rats and humans (Bal et al., 2011; Rabbani et al., 2010). Oligozoospermia could predispose diabetic males to subfertility or infertility (Noguchi et al., 1990). The observed decrease in sperm count was supported by diminished sperm intensity in the epididymal lumen. Treatment with TT extract has resulted in higher sperm count and epididymal sperm density which suggests that this herb protect the sperm against diabetes-induced damage.

Diabetes induces oxidative-stress has been reported to cause peroxidation of sperm membrane lipid which might interfere with membrane fluidity and transport processes (Sanocka and Kurpisz, 2004). In view of this, appearance of various abnormal sperm shapes could be due to abnormal membrane or cellular and nuclear changes induced by diabetes (Suresh et al., 2013). More studies could be needed to elucidate mechanisms underlying abnormal sperm appearances in diabetes. Treatment with TT extract prevents the increase in the amount of testis LPO in diabetic rats. In both diabetic rats (Nelli et al., 2013) and humans (Karimi et al., 2011), LPO was the major cause of sperm damage. Administration of TT extract to diabetic rats alleviates oxidative stress via
several mechanisms which include reduced amount of free radicals such as superoxide and preservation of total antioxidant capacity via main tainting near normal activity level of endogenous enzymatic/non-enzymatic antioxidant. The later effects may be attributed to higher amount of total phenolic content in the TT extract as revealed by phytochemical analysis. Meanwhile, ability of TT extract to lower lipid profile levels in diabetic rats could also help to reduce the risk of acquiring abnormal sperm morphology and characteristics and sperm oxidative stress (Kanter et al., 2012). Scarano et al. (2006) reported that sperm counts in diabetic rats diminished following short-term exposure to hyperglycemia, while Amaral et al. (2006) reported that prolonged hyperglycemia in rats adversely affect sperm concentration and motility due to oxidative stress.

Saponins, one of the active components of TT, have been proposed to regulate lipid metabolism (Yang et al., 1999) and hyperglycemia (Li et al., 2002). This protective reaction observed after TT treatment might also be related to the action of the saponin component of TT extract affecting lipid profile parameters.

It is well known that insulin activates enzyme lipoprotein lipase, which hydrolyzes triglyceride under normal condition. Hence, STZ induced diabetic rats have altered lipid profile. In this study, diabetic control rats exhibited significantly elevated cholesterol and triglyceride, LDL-c and VLDL-c levels as compared to normal control rats. Chronic administration of TT-extract and MET significantly reduced all the previous parameters. Therefore, normalization of lipids in diabetic rats treated with TT extract may be partly due to its stimulatory effect on insulin secretion from pancreatic β-cells (confirmed by serum insulin levels).

Histopathological changes revealed marked degeneration of most seminiferous tubules including atrophied seminiferous tubules with absence of spermatogenic series and sperms in tubular lumen (Figure 3D) and decrease in both diameter of seminiferous tubules and height of germinal epithelium of testes and epididymis as compared to those in the normal controls. These changes may be due to DM which induces subtle molecular changes that are important for sperm quality and function and alters conventional sperm parameters. Various mechanisms may explain the sperm damage observed in patients with DM. These include endocrine disorders, neuropathy, and increased oxidative stress (La Vignera et al., 2012). These effects may due to DM which decreases serum testosterone levels (Shalaby and Mouneir, 2010; Maiorino et al., 2014) which are associated with a steriodogenetic defect in Leydig cells. Furthermore, DM is associated with an increased oxidative stress, which damages sperm nuclear and mitochondrial DNA. Finally, spermatogenesis derangement and germ cell apoptosis in type 1 DM may relate to a local autoimmune damage, whereas insulin resistance, obesity, and other related comorbidities may impair sperm parameters and decrease testosterone serum levels in patients with Type 2 DM (La Vignera et al., 2012).

Oral administration of the plants extracts to the diabetic rats for 60-days caused enhancement of the histological changes of both testes and epididymis besides enhancing the diameter of seminiferous tubules, diameter of epididymal tubules and height of epithelium of testes and epididymis. These results indicate that extract of plant used in this study act to attenuate the degenerative changes in testes and epididymis because it contains many compounds that act separately or synergistically to enhance testes function and retard normal value. This may due to presence of some phytochemical compounds such as saponin, flavones, tannins and terpenes and its action can be related to insulin-like action and had ability to induce DNA repair systems due to antioxidant activities which reduce or prevent generation of free radicals. The results of this study were confirmed by Gauthaman et al. (2003) using non-castrated rats at various TT concentrations (2.5, 5 and 10 mg/kg). They study also confirmed an increase in pressure, which is a widely accepted index of penile erection. Further studies showed increases in testosterone and dihydrotestosterone, indicating a T. terrestris-induced increase in male sex hormones (Gauthaman and Ganesan, 2008).

Conclusion

The results indicate improved testicular and epididymal and reduced sperm abnormalities by oral chronic administration of TT extract used in this study, suggesting its protective potential against spermatotoxic and testicular toxicity in diabetic male rats. Based on the reduced sperm abnormalities, antihyperglycemic, antioxidant, antihyperlipidemic and histological changes exhibited by TT-extract, it can be suggested that the extract could be useful in reducing the male reproductive defects associated with DM. Although the MET decreased the glucose level in blood more than TT extract, but TT extract administration improved most of lipid profile and oxidative parameters more than MET. The present investigation has opened an excellent opportunity in the development of herbal formulation from TT extract to control diabetes.

Conflict of interest

The authors declare that they have no conflict of interest.

REFERENCES


Full Length Research Paper

Investigating extemporaneous compounding practices in the Polokwane tertiary hospital pharmacies in South Africa - a pilot study

Euphenia Mathebule Masupye¹,², Fatima Suleman²* and Thirumala Govender²

¹Department of Pharmacy, University of Limpopo, Turfloop Campus, South Africa.
²Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Westville Campus, South Africa.

Received 27 January, 2015; Accepted 29 September, 2015

Medicine availability is an important aspect of providing good quality healthcare. Some medicines are available in doses that are not suitable for a specific population group such as children or geriatric patients. Manipulation of the existing medication is undertaken instead. Studies on the practices, frequency and extent of extemporaneous compounding have been undertaken in countries such as New Zealand, Australia, United States of America and Mexico. No data exists for South Africa. Therefore the aim of the study was to explore the level of extemporaneous compounding skills at public hospital level, and to assess whether compounding is occurring in their pharmacies.

A quantitative research approach applying the cross-sectional research design was used to determine the extemporaneous compounding practices in a tertiary hospital pharmacy. Twenty five pharmacists responded to a questionnaire on their knowledge and practices. Data was collected from 691 batch records and prescriptions dating from the January 1, 2008 to December 31, 2009 to determine the frequency and extent of extemporaneous compounding. Nearly all (96%) of the responding pharmacy personnel indicated having received compounding training skills through supervision by experienced pharmacists. Seventy two percent explained that they compounded medication due to the unavailability of certain prescribed drugs. In addition, 60% of the respondents confirmed that the expiry date is personally developed. The most compounded medicines were dermatological preparations (46.60%). The findings suggest that there seem to be insufficient skills within the tertiary hospital pharmacy staff for small scale compounding and identified the need for more research into this practice.

Key words: Extemporaneous, compounding, quality, quality assurance.

INTRODUCTION

The global and chronic lack of licensed medicines and appropriate dosage forms and strength for specific groups of patients is widespread, and has sparked the initiation of extemporaneous compounding practice worldwide (Brion et al., 2003; Giam et al., 2012). The need for extemporaneous compounding is also observed...
in cases of rare disease conditions that require tailor-made therapy for a specific patient (Salgado et al., 2005; Spark, 2014). Other reasons for extemporaneous compounding are sensitivity/allergy to certain excipients and preservatives, different dose availability or different routes of administration required, or compliance problems related to the use of some medications, for example, palatability of the formulation/medicine (Feldschuh, 2008; Spark, 2014). The dose or the dosage form registered as such might not be suitable or appropriate for paediatrics, geriatrics, or those adults who are unable to swallow solid dosage forms, and those in whom medication is administered in a liquid form through naso-gastric tubes due to poor swallowing reflexes necessitating extemporaneous compounding (Standing and Tuleu, 2005; Kairuz et al., 2007a; Giam et al., 2012).

All these problems, coupled with pervasive lack of commercially available suitable drugs, have thus resulted in the need to make use of extemporaneous preparations in most hospital pharmacies. Giam and McLachlan (2008) defined extemporaneous compounding as the extemporaneous preparation, mixing, packaging or labeling of a drug as the result of a practitioner’s prescription drug in order to meet an individual patient’s need. They may be formulated from existing dosage forms (Brion et al., 2003; Haywood and Glass, 2007; Spark, 2014), which entails crushing commercially available tablets and capsules contents into a suitable liquid dosage form, with the aim of providing accessible essential medications to among others patients who are unable to swallow solid dosage forms (Nahata and Allen, 2008).

On the other hand, in the United States of America, the Food and Drug Administration (FDA) regards traditional pharmacy compounding as the extemporaneous combining, mixing, or altering of ingredients by a pharmacist, in response to a physician’s prescription to create a medication tailored to the specialized medical needs of an individual patient. Traditional compounding typically occurs when a regulatory body-approved drug is unavailable or a licensed healthcare provider decides that an approved drug is not available in the appropriate dosage form for his or her patient’s medical needs. Extemporaneous compounding may again occur in a case of the manipulation of the product’s strength suitable for adult use, where the prescriber needs a lesser strength for an infant (Kairuz et al., 2007b). Improperly compounded, adulterated drugs have the potential to cause significant harm to patients (Food and Drug Administration, 2006).

The global lack of documented and standardized formulae poses a high risk to patients as there may be variation in manufacturing methods used. Furthermore, the excipients used may differ greatly, and their effect on the stability and quality of the compounded product cannot be guaranteed (Shah et al., 2013). The Food and Drug Administration survey (Food and Drug Administration, 2006) emphasized that without strict observance of good manufacturing practice guidelines, it is possible to have miscalculations of the respective quantities of each ingredient, and this could be problematic especially where the system and processes are not tightly regulated. There have been a number of problems reported in recent years due to a lack of quality assurance processes. For example, in the United States of America a 2012 meningitis outbreak was tied to the now-shut New England Compounding Center in Framingham that killed at least 64 people and sickened 750 more. Inspections subsequently found unsanitary conditions at the company’s facility (Shaughnessy, 2012). Between March and April 2013, the FDA requested a number of voluntary nationwide recalls for compounded products due to a lack of sterility assurance (Eisler and Schnaars, 2014). In South Africa in the last decade, problems were also detected with the mixing of traditional medicines and conventional drugs that had serious adverse effects (Snyman et al., 2005).

While most countries such as New Zealand (Kairuz et al., 2007a), Australia (Feldschuh, 2008), United Kingdom (Steward et al., 2007), United States of America (Treadway et al., 2007), the Netherlands (Giam and McLachlan, 2008) and Mexico (Flores-Perez et al., 2008) have undertaken studies to determine the skills of staff compounding medicines, as well as the frequency and extent of extemporaneous compounding, no data exists for South Africa. Such studies are essential for improving the care of patients, especially because of the high prevalence of HIV/AIDS South Africa is facing, and especially for the compounding that takes place for paediatric preparations. Pharmacists in the hospital settings are responsible for assuring the quality of all compounded preparations according to Nunn (2003).

This is largely due to their professional obligation and training enabling them to perform extemporaneous compounding and also being cautious in making sure that all formulations are followed to the letter in order to maintain acceptable compounding standards. Compounding skill is a required competency for practice for registered pharmacists in many countries, more especially in New Zealand (Kairuz et al., 2007a). The purpose of this pilot study was to determine if the practice and extent of compounding, to determine the skills set and capacity of the staff compounding medicines, in order to raise the standards of compounding and prevent the risk of patient harm.

MATERIALS AND METHODS

In this study extemporaneous preparations were defined as products made or compounded in a pharmacy on a small scale to
meet a specific patients’ specific requirements of all age groups (Brion et al., 2003; Gross, 2005; Schultz, 2007), or a tailored therapy for a specific patient. For this study, the practice of extemporaneous compounding focused on small scale manufacture of preparations, using raw materials, or commercially available dosage forms, to reformulate a suitable dosage form at an appropriate strength for a specific patient of any age group. This was a cross sectional descriptive pilot study, that took place in the Polokwane Municipality, which is in the Capricorn District of Limpopo Province, South Africa, and has 44% of the district’s (Statistics South Africa, 2007). The tertiary hospital complex (made up of two hospitals) in the province was purposively selected as the site of study as it is a referral hospital with medical specialty mix at its disposal and it had 450 beds. The were 59 pharmacy personnel consisting of pharmacists, community pharmacists, pharmacy interns, pharmacist assistants and auxiliary service officers (in 2009) that were present in the two pharmacies (Limpopo Department of Health and Social Development, 2008). Thus, a purposeful sampling was conducted to select the pharmacists. A self-administered close-ended and open-ended questionnaire was designed to collect information from pharmacists and pharmacy managers for characterization of the compounding practice processes for Quality Assurance on seven items, namely;

(a) The pharmacist’s demography
(b) The education level
(c) Class of personnel
(d) Training methods
(e) Policies and procedures for extemporaneous compounding
(f) How expiry dates are determined
(g) The challenges of compounding
(h) The most common reasons for extemporaneous compounding.

The questionnaire was adopted from Treadway et al. (2007), and then modified to include additional variables, such as the challenges and reasons for extemporaneous compounding. The researchers elected to use self-administered questionnaires so that it could be completed during the pharmacists’ spare time and final collection was after six months. The participants’ identification was coded for anonymity. Pharmacists willing to participate in the study signed the consent form and completed the questionnaire after information about the study was explained by the researcher. The study was conducted between January 1, 2008 and December 31, 2009. In order to assess the frequency and the extent of extemporaneous compounding in the two hospital pharmacies of the Polokwane Municipality, retrospective data collected on a modified data sheet designed by Kairuz et al. (2007a) was used. All the batch records from January 1, 2008 to December 31, 2009 were purposively sampled. The data collection sheet was amended to provide the following information: The name of the compounded drug, quantity produced, route of administration, dosage form, storage conditions, expiry date, and date of preparation (to ensure that the study date inclusion criteria was met). Retrospective data were collected on site using the data collection sheet to determine the number of extemporaneously compounded preparations prescribed out of the total number of prescriptions for each month during the period of the study, January 2008 to December 2009. This measured the extent of extemporaneous compounding. A purposeful sampling was conducted to select the prescriptions. Delays in accessing data, as well as data being unavailable for the period beyond December 2009 (batch records being lost and prescriptions being filed elsewhere) resulted in delays in data analyses and publication of results. However, there have been no new interventions in terms of policies on extemporaneous compounding, further education requirements in this area, or in terms of pharmacy personnel employed at the study hospital. As such the results are still valid for the current period.

All extemporaneously compounded preparations in the data collection sheet were coded on a coding sheet and captured on the Microsoft Excel. All variables for assessing the frequency and the extent of extemporaneous compounding were coded and captured as well on the Microsoft Excel. The scale questions from the pharmacist questionnaire was coded from “1” to “4” with “1” representing “Never” and “4” representing “Always”. “Yes” and “No” were coded “1” “2”, respectively. All questionnaires were coded and captured into Microsoft Excel. The analysis consisted of descriptive and analytical components. This was done using Statistics Package for Social Sciences (SPSS Version 20, 2011).

Ethical considerations

Written permission to conduct the study was sought from and granted by the Research Ethics Committees (HSS/0984/2009) of the University of KwaZulu-Natal, the Limpopo Provincial Department of Health and Social Development and the hospital Chief Executive Officer (CEO).

RESULTS

Fifty-nine questionnaires were distributed to tertiary hospital pharmacy personnel. Only 25 were returned, resulting in 42.37% response rate. The low response rate was due to non-availability of respondents to participate because they verbally mentioned large daily workload as a reason. The demographic profile of the sample indicated that the majority of the pharmacists were female (56%) (Table 1). Pharmacy personnel in the age range of 20 and 30 years made up 36% of the sample, while those in the age range 31 to 40 comprised 32% of the sample.

Expertise of personnel

There was an equal distribution of senior pharmacists (20%) and registered pharmacy assistants (20%) in the personnel category with principal pharmacists and pharmacist interns making up the next biggest percentage (16% each). With regard to the pharmacists’ level of education, 64% indicated Bachelor of Pharmacy to be their highest level of education. There were 32% that still had the previous qualification of Honours in Pharmacy. Almost all of the pharmacists (96%) reported receiving compounding skills training, with 80% agreed to be receiving training through supervision by experienced pharmacists as compared to 64% that stated they received their experience via personal experience. Training content (Table 2) included information sourcing (56%), use of reference materials (68%), use of equipment like weighing scales, compounding tile for creams and ointments (96%), labeling according to recommended guidelines (92%), compounding record
Table 1. Demographic profile as percentages of the total sample.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number (n = 25)</th>
<th>Frequency</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>14</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>23</td>
<td>92.0</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>2</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 - 30</td>
<td>9</td>
<td>36.0</td>
<td></td>
</tr>
<tr>
<td>31 - 40</td>
<td>8</td>
<td>32.0</td>
<td></td>
</tr>
<tr>
<td>41 - 50</td>
<td>7</td>
<td>28.0</td>
<td></td>
</tr>
<tr>
<td>51 - 60</td>
<td>1</td>
<td>4.0</td>
<td></td>
</tr>
<tr>
<td>Personnel category</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal pharmacist</td>
<td>4</td>
<td>16.0</td>
<td></td>
</tr>
<tr>
<td>Senior pharmacist</td>
<td>5</td>
<td>20.0</td>
<td></td>
</tr>
<tr>
<td>Pharmacist</td>
<td>3</td>
<td>12.0</td>
<td></td>
</tr>
<tr>
<td>Pharmacist intern</td>
<td>4</td>
<td>16.0</td>
<td></td>
</tr>
<tr>
<td>Registered pharmacy assistant</td>
<td>5</td>
<td>20.0</td>
<td></td>
</tr>
<tr>
<td>Community pharmacist</td>
<td>2</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td>Pharmacy assistant basic</td>
<td>2</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td>Personnel qualification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bachelor of Pharmacy</td>
<td>16</td>
<td>64.0</td>
<td></td>
</tr>
<tr>
<td>Honours in Pharmacy</td>
<td>8</td>
<td>32.0</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Compounding skills training areas.

<table>
<thead>
<tr>
<th>Which training areas are covered in your training?</th>
<th>Agree (%)</th>
<th>Frequency (n=25)</th>
<th>Disagree (%)</th>
<th>Frequency (n=25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sourcing formulation</td>
<td>56</td>
<td>14</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Use of references</td>
<td>68</td>
<td>17</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Use of equipment, mortar and pestle, balances etc.</td>
<td>96</td>
<td>24</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Labeling</td>
<td>92</td>
<td>23</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Compounding record keeping</td>
<td>92</td>
<td>23</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Formulation record keeping</td>
<td>80</td>
<td>20</td>
<td>20</td>
<td>5</td>
</tr>
<tr>
<td>Aseptic technique</td>
<td>12</td>
<td>3</td>
<td>88</td>
<td>22</td>
</tr>
<tr>
<td>Other</td>
<td>24</td>
<td>6</td>
<td>76</td>
<td>19</td>
</tr>
</tbody>
</table>

The study found 92% availability of compounding policies and procedures for the production of the same product for different batches. Furthermore, there were no proof of records kept on regular calibration of electronic weighing scales (76%) and maintenance (72%). The pharmacy personnel were asked how often the following listed records (Table 3) were included in the documentation of their pharmacy. Documentation for compounding comprised of a manufacturing batch record and are always kept (80%), and compounding formula and procedures at 72% (Table 3). A logbook of all compounded items is always kept (64%). The study further revealed that maintenance of weighing scales is never carried out at 64%. Table 4 below shows resources which the pharmacy personnel use for obtaining compounding formulations. The source of compounding formulations were either from published literature (40%) or self-reports on in-house formulations which are personally developed (28%). According to the pharmacists, the hospital has compiled and used a formulation document containing the formulation of a
Table 3. Documentation of compounding in the hospital.

<table>
<thead>
<tr>
<th>How often are the following listed records included in the documentation of this pharmacy?</th>
<th>Never (%)</th>
<th>Sometimes (%)</th>
<th>Often (%)</th>
<th>Always (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturing batch records</td>
<td>4</td>
<td>8</td>
<td>8</td>
<td>80</td>
</tr>
<tr>
<td>Compounding formulae and direction for compounding</td>
<td>8</td>
<td>4</td>
<td>16</td>
<td>72</td>
</tr>
<tr>
<td>A log of all compounded items*</td>
<td>4</td>
<td>8</td>
<td>20</td>
<td>64</td>
</tr>
<tr>
<td>Balance maintenance log books*</td>
<td>64</td>
<td>4</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>Standard Operating Procedures*</td>
<td>12</td>
<td>8</td>
<td>24</td>
<td>52</td>
</tr>
</tbody>
</table>

* Missing values for these variables is 4%.

Table 4. Resources used for obtaining formulations in hospital pharmacy.

<table>
<thead>
<tr>
<th>What resources do staff members use for obtaining formulations in compounding?</th>
<th>Percentage</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Published literature</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Other hospitals</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>Other pharmacies</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>In-house; personally developed</td>
<td>28</td>
<td>7</td>
</tr>
<tr>
<td>Missing</td>
<td>12</td>
<td>3</td>
</tr>
</tbody>
</table>

Table 5. Establishing expiry dates.

<table>
<thead>
<tr>
<th>Establishment of expiry dates</th>
<th>N = 19 (6 missing, 24%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Agree (%)</td>
</tr>
<tr>
<td>In-house stability testing</td>
<td>4</td>
</tr>
<tr>
<td>External stability testing</td>
<td>4</td>
</tr>
<tr>
<td>Recommendations from other hospital pharmacies</td>
<td>4</td>
</tr>
<tr>
<td>Recommendations from other pharmacies</td>
<td>4</td>
</tr>
<tr>
<td>Personally established dates</td>
<td>60</td>
</tr>
<tr>
<td>Missing</td>
<td>24</td>
</tr>
</tbody>
</table>

In terms of determining an expiry date, results shown in Table 5 revealed that 60% of the respondents confirmed that the expiry date is personally developed. There was inconsistency in documenting these dates. No stability and quality control tests are carried out to assess physical, chemical and microbiological changes or for the suitability of the formulation in terms of the active material content and shelf-life.

The pharmacy personnel were asked about the challenges they encounter in the preparation of compounded product, and they strongly agreed (96%) that formulations were available in the pharmacy and that calculations were not (84%) a challenge.

Standard Operating Procedures were not revised, however (72%). The main reasons for compounding were unavailability of prescribed drug (72%); unsuitable dosage form (44%) and unsuitable route of administration (32%).

The extent and frequency of compounding

The results for the extent of compounding were assessed by reviewing 691 batch records. There was an average of 27.64% preparations compounded per month with the compounding frequency of 57.6% in 2008 and 42.4% in 2009. Solutions accounted for more than 43.9% of the most frequently compounded dosage formulation. This study revealed that dermatologicals, that is, creams and ointments totalling 33.0 and 13.60%, respectively are
mostly compounded at the hospital. The most compounded products were Betamethasone (27.9%) and Corticosteroid (32.9%). The shelf-life given for extemporaneously compounded preparations was found to be ranging from 6 months (66.3%), 3 months (14.5%) and 12 months (9.8%).

A considerable number (98.30%) of extemporaneously compounded preparations were reported to be stored below 25°C. Only 1.70% were refrigerated at 2 - 8°C. The refrigerated solutions were found to be the oral solutions containing minerals for supplementation. The other dosage forms and other oral and non-oral solutions were stored below 25°C. Most of the preparations were extemporaneously prepared from commercially available drugs where the prescriber needed lesser strength for a specific patient condition, irrespective of the patients’ age.

DISCUSSION

Compounding errors are an emerging and serious problem. Pharmacists hold a unique position as health professionals who are formally trained in compounding medications and licensed to dispense them. This research attempted to gain an understanding of compounding practices in the tertiary hospital pharmacies in the Polokwane Municipality, as a follow up of Treadway et al. (2007) who noted that there are serious questions about the quality of compounded preparations. Most of the pharmacists in this study received their training as part of the undergraduate curriculum. Eley and Birnie (2006) indicated that pharmacy students do not adequately retain compounding knowledge and skills, but that pharmacy students’ level of competency and retention of knowledge with respect to compounding capsules is not adequately retained after a 12-month hiatus. Different findings of the training on compounding skills (69%) were reported in Texas by Treadway et al. (2007). Treadway and colleagues cited a study by Morris et al. (2003) with a training rate of 96% for pharmacists and 89% for technicians. A key finding of this study is the limited training in aseptic technique, which if not followed properly could result in contamination of compounded products. There is thus a need to look at competency assessments for compounding pharmacists as well as continuous professional development in this area.

This study indicated that extemporaneous compounding is not subjected to a quality control procedure beyond calculations, ingredients checking and visual inspection which is in agreement with the findings from Donnelly et al. (2008). This is in contrast to the quality control operations pertaining to proprietary products manufactured by the pharmaceutical industry, where GMP standards are followed Donnelly et al. (2008). The study found 92% availability of compounding policies and procedures, compared to the findings by Treadway et al. (2007) of 71% of pharmacies in Texas. In Treadway et al. (2007) study, two third of the pharmacies responded to have no policies and procedures and did not provide staff training. This study results also contradict Treadway et al. (2007) findings as in that study, 82% of pharmacists used published literature and 40% of formulations were personally developed despite the emergence of more established sources for compounding formulations. Treadway et al. (2007) found that unsuitable dosage forms as a reason for compounding was found to be the lowest (16%) and cost at 50% was the main reason for compounding. This study found that the unavailability of the prescribed medicine was the main driver for compounding. There have been attempts in the past decade according to Treadway et al. (2007) to raise the standard of all compounding practices through the efforts of the United States Pharmacopeia (USP) and the American Society of Health-System Pharmacists (ASHP) through ASHP guidelines on Quality Assurance for Pharmacy - Prepared Sterile Products in 2000. More recently, USP has put further procedures and requirements on compounding non-sterile and sterile preparations in an attempt to help raise the standards of compounding and prevent the risk of patient harm. This is largely absent in South Africa.

This study indicated a frequency of compounding at this hospital of between 40 and 50%. In the United States, it has been estimated that approximately 1% of prescriptions are compounded, representing nearly 30 million prescriptions annually. A similar estimate has been made for compounded prescriptions produced in Australia (Giam et al., 2012). This study revealed that pharmacy compounding consists mostly of dermatological products and dermatological dosage forms. In a study by Buurma et al. (2003) who evaluated the frequency of compounding in the Dutch community pharmacies, the findings were that it consisted largely by dermatological preparations and dermatological dosage forms. A contrary result was found by Kairuz et al. (2007a) in the New Zealand hospital sample survey in determining the extent and nature of compounding, where oral suspensions were the most compounded dosage form with a reformulation of Omeprazole being the most frequently compounded drug.

The shelf-life given for extemporaneously compounded preparations was found to be 3 months, 6 months and 12 months. However, there are some products which should be used within 24 h of preparation. According to Brion et al. (2003), an unpublished United Kingdom survey showed that 54% of 112 pediatric extemporaneous formulations had inadequate data on shelf-life. This is due to the extensive research that will need to be undertaken to establish the suitability of the formulation.
on its stability. Lack of time, expertise and facilities in hospital pharmacies, among others, limit the undertaking of such research.

CONCLUSION AND RECOMMENDATION

This pilot study has indicated that compounding is occurring in South Africa, but there is a need for training and for a standardized compendium of formulation for quality assurance reasons. There is a need for professional organizations to play a role as a source of compounding formulations and quality assurance guidelines. This could be a way to increase the quality of available formulas by using a central source of information as well as guidelines for expiry date determination and equipment calibration among other quality assurance processes. However, as this is a pilot, there is a need for more research in the compounding practices in both public and private sector facilities in South Africa in order to avoid any compounding contaminations or errors that could result in patient harm or even death.

Conflicts of interest

The authors declare that there are no conflicts of interest.

ACKNOWLEDGEMENTS

We thank Mr GT Mahlatsi for the assistance in conceptualising the study, The University of Limpopo for financial assistance, The Limpopo Provincial Department of Health and Social Development for granting me permission to conduct the study in the province.

REFERENCES

Gross Z (2005). Why special manufacturing units are needed now as much as they were ever. Pharm. J. 275:743-744.
African Journal of Pharmacy and Pharmacology

Related Journals Published by Academic Journals:

- Journal of Medicinal Plant Research
- African Journal of Pharmacy and Pharmacology
- Journal of Dentistry and Oral Hygiene
- International Journal of Nursing and Midwifery
- Journal of Parasitology and Vector Biology
- Journal of Pharmacognosy and Phytotherapy
- Journal of Toxicology and Environmental Health Sciences